SHANNON RONCA to Spike Glycoprotein, Coronavirus
This is a "connection" page, showing publications SHANNON RONCA has written about Spike Glycoprotein, Coronavirus.
Connection Strength
0.543
-
Recombinant Rod Domain of Vimentin Reduces SARS-CoV-2 Viral Replication by Blocking Spike Protein-ACE2 Interactions. Int J Mol Sci. 2024 Feb 20; 25(5).
Score: 0.197
-
Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine. 2021 10 29; 39(45):6601-6613.
Score: 0.167
-
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452. Vaccine. 2023 03 24; 41(13):2184-2197.
Score: 0.046
-
From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):495-500.
Score: 0.046
-
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. Vaccine. 2022 06 09; 40(26):3655-3663.
Score: 0.044
-
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine. 2022 02 23; 40(9):1253-1260.
Score: 0.043